Literature DB >> 17948932

Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease.

Mayumi Kawada1, Atsuko Arihiro, Emiko Mizoguchi.   

Abstract

Inflammatory bowel disease (IBD), the most important being Crohn's disease and ulcerative colitis, results from chronic dysregulation of the mucosal immune system in the gastrointestinal tract. Although the pathogenesis of IBD remains unclear, it is widely accepted that genetic, environmental, and immunological factors are involved. Recent studies suggest that intestinal epithelial defenses are important to prevent inflammation by protecting against microbial pathogens and oxidative stresses. To investigate the etiology of IBD, animal models of experimental colitis have been developed and are frequently used to evaluate new anti-inflammatory treatments for IBD. Several models of experimental colitis that demonstrate various pathophysiological aspects of the human disease have been described. In this manuscript, we review the characteristic features of IBD through a discussion of the various chemically induced experimental models of colitis (e.g. dextran sodium sulfate-, 2,4,6-trinitrobenzene sulfonic acid-, oxazolone-, acetic acid-, and indomethacin-induced models). We also summarize some regulatory and pathogenic factors demonstrated by these models that can, hopefully, be exploited to develop future therapeutic strategies against IBD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17948932      PMCID: PMC4172737          DOI: 10.3748/wjg.v13.i42.5581

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  186 in total

Review 1.  Toll-like receptors: linking innate and adaptive immunity.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

2.  Homeostatic regulation of intestinal epithelia by intraepithelial gamma delta T cells.

Authors:  H Komano; Y Fujiura; M Kawaguchi; S Matsumoto; Y Hashimoto; S Obana; P Mombaerts; S Tonegawa; H Yamamoto; S Itohara
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

3.  Therapeutic effect of adenoviral-mediated hepatocyte growth factor gene administration on TNBS-induced colitis in mice.

Authors:  Tomoyuki Mukoyama; Takamasa Kanbe; Rie Murai; Yoshiyuki Murawaki; Takashi Shimomura; Ko-Ichi Hashiguchi; Toshiya Saeki; Miho Ichiba; Yoko Yoshida; Naotada Tanabe; Akihiro Kurimasa; Ken-Ichi Harada; Kazuo Yashima; Ichiro Hisatome; Hisao Ito; Yoshikazu Murawaki; Goshi Shiota
Journal:  Biochem Biophys Res Commun       Date:  2005-04-22       Impact factor: 3.575

4.  Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation.

Authors:  Torsten Kucharzik; Andreas Lugering; Yutao Yan; Adel Driss; Laetitia Charrier; Shanthi Sitaraman; Didier Merlin
Journal:  Lab Invest       Date:  2005-07       Impact factor: 5.662

5.  Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis.

Authors:  Minoru Matsuura; Kazuichi Okazaki; Akiyoshi Nishio; Hiroshi Nakase; Hiroyuki Tamaki; Kazushige Uchida; Toshiki Nishi; Masanori Asada; Kimio Kawasaki; Toshiro Fukui; Hazuki Yoshizawa; Shinya Ohashi; Satoko Inoue; Chiharu Kawanami; Hiroshi Hiai; Yasuhiko Tabata; Tsutomu Chiba
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

6.  The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis.

Authors:  Ivan J Fuss; Monica Boirivant; Brian Lacy; Warren Strober
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

7.  Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice.

Authors:  Tatsuya Ohkawara; Jun Nishihira; Hiroshi Takeda; Shuhei Hige; Mototsugu Kato; Toshiro Sugiyama; Toshihiko Iwanaga; Hideki Nakamura; Yuka Mizue; Masahiro Asaka
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

8.  Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation.

Authors:  David Philippe; Laurent Dubuquoy; Hervé Groux; Valérie Brun; Myriam Tran Van Chuoï-Mariot; Claire Gaveriaux-Ruff; Jean-Frédéric Colombel; Brigitte L Kieffer; Pierre Desreumaux
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

9.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B.

Authors:  Ian C Lawrance; Feng Wu; André Z A Leite; Joseph Willis; Gail A West; Claudio Fiocchi; Shukti Chakravarti
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

10.  Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.

Authors:  Chong Shen; Dominique Bullens; Ahmad Kasran; Philippe Maerten; Louis Boon; Johannes M F G Aerts; Gert Van Assche; Karel Geboes; Paul Rutgeerts; Jan L Ceuppens
Journal:  Int Immunopharmacol       Date:  2004-07       Impact factor: 4.932

View more
  73 in total

1.  Induction of murine TNBS colitis is strictly controlled by a modified method using continuous inhalation anesthesia with sevoflurane.

Authors:  Tomohiro Terai; Satoshi Osawa; Shinya Tani; Shinji Oishi; Yoshifumi Arai; Takanori Yamada; Mitsushige Sugimoto; Takahisa Furuta; Shigeru Kanaoka; Hiroaki Miyajima; Ken Sugimoto
Journal:  Dig Dis Sci       Date:  2014-01-23       Impact factor: 3.199

Review 2.  An expanding stage for commensal microbes in host immune regulation.

Authors:  Yan Shi; Libing Mu
Journal:  Cell Mol Immunol       Date:  2017-01-09       Impact factor: 11.530

3.  2,4,6-trinitrobenzene sulfonic acid-induced chronic colitis with fibrosis and modulation of TGF-β1 signaling.

Authors:  Emilien Loeuillard; Julien Bertrand; Anni Herranen; Chloé Melchior; Charlène Guérin; Moïse Coëffier; Moutaz Aziz; Pierre Déchelotte; Guillaume Savoye; Rachel Marion-Letellier
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

4.  BTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis.

Authors:  Han-Xian Zhang; Bin Zhu; Xiao-Xia Fu; Jin-Cheng Zeng; Jun-Ai Zhang; Wan-Dang Wang; Bin Kong; Wen-Yu Xiang; Jixin Zhong; Cong-Yi Wang; Xue-Bao Zheng; Jun-Fa Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Differential effects of experimental ulcerative colitis on P2X7 receptor expression in enteric neurons.

Authors:  Marcos Vinícius da Silva; Aline Rosa Marosti; Cristina Eusébio Mendes; Kelly Palombit; Patricia Castelucci
Journal:  Histochem Cell Biol       Date:  2014-09-09       Impact factor: 4.304

Review 6.  Animal models of inflammatory bowel disease: a review.

Authors:  Nidhi Goyal; Ajay Rana; Abhilasha Ahlawat; Krishna Reddy V Bijjem; Puneet Kumar
Journal:  Inflammopharmacology       Date:  2014-06-07       Impact factor: 4.473

7.  Dextran sodium sulfate inhibition of real-time polymerase chain reaction amplification: a poly-A purification solution.

Authors:  T A Kerr; M A Ciorba; H Matsumoto; V R T Davis; J Luo; S Kennedy; Y Xie; A Shaker; B K Dieckgraefe; N O Davidson
Journal:  Inflamm Bowel Dis       Date:  2011-05-25       Impact factor: 5.325

8.  Combined administration of secretin and oxytocin inhibits chronic colitis and associated activation of forebrain neurons.

Authors:  Martha G Welch; Muhammad Anwar; Christine Y Chang; Kara J Gross; David A Ruggiero; Hadassah Tamir; Michael D Gershon
Journal:  Neurogastroenterol Motil       Date:  2010-03-04       Impact factor: 3.598

9.  Identification of the protective effects of traditional medicinal plants against SDS-induced Drosophila gut damage.

Authors:  Yang Zhou; Zonglin Liu; Yuchen Chen; Li Hua Jin
Journal:  Exp Ther Med       Date:  2016-08-31       Impact factor: 2.447

10.  Multifactorial patterns of gene expression in colonic epithelial cells predict disease phenotypes in experimental colitis.

Authors:  Aubrey L Frantz; Maria E C Bruno; Eric W Rogier; Halide Tuna; Donald A Cohen; Subbarao Bondada; R Lakshman Chelvarajan; J Anthony Brandon; C Darrell Jennings; Charlotte S Kaetzel
Journal:  Inflamm Bowel Dis       Date:  2012-02-22       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.